Neoplasm by Special Category

In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to ve… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. Cytoplasmic … (full text at CIViC)

PMID 17590872 · Kato et al., 2007 · Open in CIViC

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC)

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved t… (full text at CIViC)

PMID 22842582 · Grell et al., 2012 · Open in CIViC

Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably ove… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model.

PMID 27297869 · Stottrup et al., 2016 · Open in CIViC

Overexpression of AKT3 in lumenal breast cancer cell line SKBR3, which does not express the AKT3 isoform, induced a statistically significant 2.7 fold increase in IC50 for pan-AKT inhibitor GSK690693.… (full text at CIViC)

PMID 24335962 · Chin et al., 2014 · Open in CIViC

112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALD… (full text at CIViC)

PMID 24708484 · Sim et al., 2014 · Open in CIViC

IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or AL… (full text at CIViC)

PMID 26634247 · Seidensaal et al., 2015 · Open in CIViC

ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 non–HPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protei… (full text at CIViC)

PMID 23635773 · Kostareli et al., 2013 · Open in CIViC

FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrea… (full text at CIViC)

PMID 26634247 · Seidensaal et al., 2015 · Open in CIViC

Expression of an alternative ALK transcript (ATI), encompassing exons 20–29 preceded by ~400 base pairs (bp) of intron 19, but not exons 1–19 was identified in three samples of thyroid cancer and mela… (full text at CIViC)

PMID 26444240 · Wiesner et al., 2015 · Open in CIViC

Expression of the ALK alternative transcript isoform (ATI) in Ba/F3 cells resulted in phosphorylation of ALK and IL3-independent growth in vitro, while ALK ATI expressing NIH-3T3 cells induced tumorig… (full text at CIViC)

PMID 26444240 · Wiesner et al., 2015 · Open in CIViC

In the same Children's Oncology Group analysis of 242 pretherapy high-risk neuroblastoma tumours from the phase III ANBL0532 trial (NCT00567567), ALK amplification was detected in 8 tumours (3.3%) by … (full text at CIViC)

PMID 40036726 · Berko et al., 2025 · Open in CIViC

A 28 year-old patient with non-small cell lung cancer was found to harbor the EML4-ALK fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK C1156Y co-mutation demonstrated resistance to crizotinib treatment compared… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment… (full text at CIViC)

PMID 27049722 · Siaw et al., 2016 · Open in CIViC

Two patients with IDH wild-type, MGMT promoter unmethylated glioblastoma were treated with crizotinib. Patient 1 had weak expression of ALK in 25% of tumor tissue and polysomy of ALK in 53% of nuclei;… (full text at CIViC)

PMID 26498130 · Le Rhun et al., 2015 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK F1174C co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.

PMID 21575866 · Sakamoto et al., 2011 · Open in CIViC

SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.

PMID 18923525 · George et al., 2008 · Open in CIViC

The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neu…

In an in vitro study, a FL5.12 cell line expressing NPM-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated increased resistance to alectinib treatment (IC50: … (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated resistance to ceritinib treatment (IC50: 140.45 … (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In a phase 2 study (NCT0093245), a stage IV non-small cell lung cancer patient with acquired crizotinib resistance harbored an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib… (full text at CIViC)

PMID 24736079 · Ignatius Ou et al., 2014 · Open in CIViC

A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily. The patient showed progressive di… (full text at CIViC)

PMID 23598171 · Mossé et al., 2013 · Open in CIViC

Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of ev… (full text at CIViC)

PMID 26554404 · Infarinato et al., 2016 · Open in CIViC

From a total of 90 patients -54 boys and 36 girls- one case presented with F1245V mutation in primary neuroblastoma tumor, specimens obtained during surgery or biopsy were subjected to copy number sta… (full text at CIViC)

PMID 22085494 · Bagci et al., 2012 · Open in CIViC

Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. T… (full text at CIViC)

PMID 28183697 · Drilon et al., 2017 · Open in CIViC

A genome-wide scan of single nucleotide polymorphisms in twenty neuroblastoma families identified the ALK gene as being disease linked. Sequencing of ALK exons identified 3 mutations, including G1128A… (full text at CIViC)

PMID 18724359 · Mossé et al., 2008 · Open in CIViC

A genome-wide scan of single nucleotide polymorphisms in twenty neuroblastoma families identified the ALK gene as being disease linked. Sequencing of ALK exons identified 3 mutations, including G1128A… (full text at CIViC)

PMID 18724359 · Mossé et al., 2008 · Open in CIViC

A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28,… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1202R co-mutation. The ALK G1202R tumor was reported to be refractory t… (full text at CIViC)

PMID 23729361 · Gainor et al., 2013 · Open in CIViC

This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One ALK+ patient had a novel fusion between… (full text at CIViC)

PMID 22235099 · Doebele et al., 2012 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM-ALK and an ALK G1269A co-mutation, demonstrated increased resistance to alectinib treatment (IC50: 89.27 nmol/L), as compared to FL5.12 cells ex… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated resistance to crizotinib treatment (IC50: 871.75… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory conce… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC